How frequently should TSH be measured during pregnancy to assess the response to levothyroxine therapy?

TSH Monitoring Frequency During Pregnancy on Levothyroxine

Monitor TSH every 4 weeks throughout pregnancy until a stable dose is achieved and TSH is within the trimester-specific reference range. Once stable, continue monitoring at minimum once per trimester through delivery 1.

Specific Monitoring Algorithm

For Women Already on Levothyroxine Before Pregnancy:

• Immediately upon pregnancy confirmation: Check TSH and increase levothyroxine dose by 30% (typically 2 additional tablets per week) 2
• Every 4 weeks: Recheck TSH and adjust dose until TSH is within trimester-specific range 1
• Once stable: Continue monitoring at minimum once per trimester 1
• Postpartum: Reduce to pre-pregnancy dose immediately after delivery and recheck TSH at 4-8 weeks 1

For New-Onset Hypothyroidism Diagnosed During Pregnancy:

• Every 4 weeks: Monitor TSH after initiating or adjusting levothyroxine until target is achieved 1
• Target TSH: ≤2.5 mIU/L in first trimester, ≤3.0 mIU/L in second/third trimesters 2

Key Clinical Considerations

The 4-week monitoring interval is critical because TSH changes occur rapidly after dose adjustments, with significant decreases typically seen within 4 weeks of levothyroxine initiation 3. Research demonstrates that testing every 4 weeks identifies 92% of abnormal values during pregnancy 4.

Trimester-specific TSH reference ranges must be used:

• First trimester: 0.1-2.5 mIU/L 2
• Second/third trimesters: Upper limit of 3.0 mIU/L 2

Common Pitfalls to Avoid

1. Using non-pregnant reference ranges: The normal TSH range is physiologically lower in pregnancy, particularly in the first trimester due to hCG-mediated TSH suppression 2

2. Insufficient monitoring frequency: Monthly monitoring is essential because thyroid hormone requirements increase progressively throughout pregnancy—by 13% in first trimester, 26% in second trimester, and 26% in third trimester on average 5

3. Assuming one dose adjustment is sufficient: Research shows that 10-21% of women require multiple dose adjustments throughout pregnancy, even after initial stabilization 3

4. Forgetting etiology-specific requirements: Women with treated Graves' disease or goiter require larger dose increases (up to 51% by second trimester) compared to those with primary hypothyroidism (16% increase) 5

5. Inadequate postpartum follow-up: Failure to reduce levothyroxine to pre-pregnancy levels immediately after delivery can cause iatrogenic hyperthyroidism 1

Evidence Strength

The FDA drug label 1 provides the highest-quality guidance, explicitly stating to "monitor TSH every 4 weeks until a stable dose is reached." This is reinforced by the 2012 Endocrine Society guidelines [2-2] and supported by prospective research demonstrating that 4-week intervals effectively prevent maternal hypothyroidism while minimizing overtreatment 4.